SILO
Silo Pharma Inc. Common Stock (SILO)
Healthcare • NASDAQ • $1.16-1.78%
- Symbol
- SILO
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $1.16
- Daily Change
- -1.78%
- Market Cap
- $2.42M
- Trailing P/E
- N/A
- Forward P/E
- -1.69
- 52W High
- $10.43
- 52W Low
- $1.10
- Analyst Target
- N/A
- Dividend Yield
- 0.00%
- Beta
- 0.91
Silo Pharma, Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. In addition, the company is developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targ…
Company websiteResearch SILO on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.